Cargando…
The trans cell cycle effects of PARP inhibitors underlie their selectivity toward BRCA1/2-deficient cells
PARP inhibitor (PARPi) is widely used to treat BRCA1/2-deficient tumors, but why PARPi is more effective than other DNA-damaging drugs is unclear. Here, we show that PARPi generates DNA double-strand breaks (DSBs) predominantly in a trans cell cycle manner. During the first S phase after PARPi expos...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Cold Spring Harbor Laboratory Press
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8415318/ https://www.ncbi.nlm.nih.gov/pubmed/34385259 http://dx.doi.org/10.1101/gad.348479.121 |